TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Isabel GroteStephan BartelsLeonie KandtLaura BollmannHenriette ChristgenMalte GronewoldMieke RaapUlrich LehmannOleg GluzUlrike NitzSherko KuemmelChristine Zu EulenburgMichael BraunBahriye AktasEva-Maria GrischkeClaudia SchumacherKerstin Luedtke-HeckenkampRonald KatesRachel WuerstleinMonika GraeserNadia HarbeckMatthias ChristgenHans KreipePublished in: Cancer medicine (2021)
We conclude that impaired EPR to pET is suitable to identify cases with primary endocrine resistance in early luminal breast cancer and that TP53-mutated luminal cancers might not be sufficiently treated by endocrine therapy alone.